ArticleGlobal challenges (Hoboken, NJ)2025
How Problems with Microplastics in Research and Application Can be Overcome: Lessons From the Experience of Plastics Stakeholders.
Article in Global challenges (Hoboken, NJ), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How Problems with Microplastics in Research and Application Can be Overcome: Lessons From the Experience of Plastics Stakeholders.Global challenges (Hoboken, NJ) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential human health and environmental risks of micro- and nanoplastics (MNPs) have received increasing scientific attention in recent years. However, methodological challenges, particularly in hazard identification and exposure assessment, continue to hinder reliable risk characterization of MNPs. Taking into account the often complex composition of MNPs as a mixture of polymer, additives, and possible chemical and biological contaminants, comprehensive and robust assessments based on reproducible and harmonized protocols are needed before evidence-based regulatory decisions can be made. Furthermore, given the increasing amounts of plastics in various applications, it is already necessary to develop risk-mitigating strategies aimed at minimizing potential adverse effects on ecosystems and human health. To address 1) the need for better networking of research and standardization across the entire analytical workflow and 2) the requirements for risk-minimizing design and labeling of plastics, an expert workshop was held in the course of a Horizon 2020 research and innovation project, PlasticsFatE. The results of the event contain concrete recommendations, such as 1) a graduated approach to methodological unification with harmonization in particle and hazard analysis and standardization in monitoring, 2) a risk-minimizing design of plastics, and 3) the obligation to label toxic substances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.